GlobeNewswire Clinical StudiesOriginal article
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
Phase 1positiveNintedanib DPIPositive
AI Analysis
Summary
MannKind reported positive Phase 1b INFLO-1 results for Nintedanib DPI, demonstrating safety, tolerability, and clinical validation of its dry powder inhaler technology in idiopathic pulmonary fibrosis.
Clinical Trial Data
Phase
1b
Primary Endpoint
Met
Outcome Details
Safety and tolerability demonstrated; clinical validation of DPI technology in IPF
Importance:5/10
Sentiment:
0.75
Phase 1bIPFDPI technologysafetytolerability
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on July 29, 2026 10:30 AM